Histoplasmosis Treatment Global Market Report 2024

The global histoplasmosis treatment market has grown strongly in recent years. It will grow from $4.74 billion in 2023 to $5.13 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to geographic prevalence, awareness and diagnosis, global health initiatives, research and drug development.

The global histoplasmosis treatment market is expected to see strong growth in the next few years. It will grow to $7.04 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to telemedicine and remote consultations, patient education and support, reimbursement policies. Major trends in the forecast period include antifungal resistance management, combination therapies, immunomodulatory therapies, advanced diagnostic tools.

The surge in chronic diseases is anticipated to be a significant driver for the expansion of the histoplasmosis treatment market in the foreseeable future. Chronic illnesses, characterized by lasting three months or more and potentially worsening over time, are becoming increasingly prevalent. Histoplasmosis treatment plays a crucial role in enhancing respiratory health, mitigating inflammation, bolstering immune system function, and ultimately elevating the quality of life for individuals grappling with chronic diseases. For instance, in January 2023, as per the National Library of Medicine, a US-based agency, the population of individuals aged 50 and above in the US afflicted with at least one chronic condition is projected to surge by 99.5%, skyrocketing from 71.522 million in 2020 to a staggering 142.66 million by 2050. Consequently, the escalating incidence of chronic diseases stands as a pivotal factor propelling the growth of the histoplasmosis treatment market.

The escalating prevalence of human immunodeficiency virus (HIV) is projected to be a major driving force behind the expansion of the histoplasmosis treatment market in the foreseeable future. HIV, a virus that targets CD4 cells (T cells) and weakens the immune system's ability to combat infections and diseases, has become increasingly prevalent. Histoplasmosis treatment plays a vital role in managing the fungal infection for AIDS patients, aiding in the prevention of disseminated disease and reducing mortality through the use of antifungal medications like itraconazole or amphotericin B. For instance, as of July 2023, according to the World Health Organization, a Switzerland-based United Nations agency, there were 39 million reported cases of HIV globally in 2022, resulting in 630,000 deaths from HIV-related causes. Consequently, the mounting prevalence of HIV is a key driver in the growth of the histoplasmosis treatment market.

The shortage of awareness surrounding histoplasmosis is expected to hinder the expansion of the treatment market for this condition in the foreseeable future. Histoplasmosis, stemming from the Histoplasma fungus present in soil, poses a risk to individuals, especially those in proximity to contaminated materials. This fungal infection is commonly contracted through the inhalation of spores present in bird and bat droppings. For instance, as of June 2023, as reported by the U.S. Department of Health and Human Services, the diagnosis of histoplasmosis may experience delays due to a lack of sufficient awareness regarding the condition. Histoplasmosis is not categorized as a notifiable disease and is excluded from most public health surveillance systems, making it difficult to accurately gauge its true prevalence. Consequently, the limited awareness surrounding the disease stands as a significant obstacle impeding the growth of the histoplasmosis treatment market.

Key players in the histoplasmosis treatment market are pioneering inventive approaches to fortify their market presence. Breakthroughs in antifungal drug research have paved the way for novel compounds and strategies specifically designed to combat invasive histoplasmosis. For instance, in June 2022, Apex Laboratories, an India-based pharmaceutical company, unveiled an advanced iteration of Itraconazole Capsules Supra Bioavailable in 65 and 130 mg variants - a potent therapeutic option for effectively managing fungal infections. These capsules deliver a remarkable 90% of active medicine to the biological system at a reduced dosage, catering to a range of fungal infections like blastomycosis, histoplasmosis, and aspergillosis. Their creation involves cutting-edge spray granulation technology, which accelerates the dissolution rate of itraconazole. This medication is uniformly present in solid dispersion, sans pellets. Such innovative techniques enhance the bioavailability of medications with low solubility.

In April 2021, the US-based biotechnology and pharmaceutical giant, Pfizer Inc., completed the acquisition of Amplyx Pharmaceuticals Inc. for an undisclosed sum. This strategic move is geared towards augmenting Pfizer's anti-infective portfolio and deepening its expertise in the realm of infectious diseases. Amplyx Pharmaceuticals Inc., also based in the United States, is renowned for its development of life-saving treatments and therapies, including crucial drugs for histoplasmosis treatment, like amphotericin B.

Major players in the histoplasmosis treatment market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol Myers Squibb, AstraZeneca PLC, Abbott laboratories, GSK PLC, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceutical Industries Ltd., Astellas pharma US Inc., Mylan N.V., Biogen Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation, AB Science, Ionis Pharmaceuticals Inc., Advanz Pharma Corp., Leadiant Biosciences, IMMY, Sigma Tau Pharmaceuticals Inc.

North America was the largest region in the histoplasmosis treatment market in 2023. The regions covered in histoplasmosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the histoplasmosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Histoplasmosis treatment encompasses a range of medical interventions and therapies aimed at combatting the fungal infection caused by the Histoplasma capsulatum fungus. This particular fungus is commonly found in soil, especially in areas where substantial accumulations of bird or bat droppings exist. The approach to treatment is tailored to factors such as the infection's severity, the overall health of the patient, and the presence of any underlying medical conditions.

This report provides histoplasmosis treatment market statistics, including histoplasmosis treatment industry global market size, regional shares, competitors with a histoplasmosis treatment market share, detailed histoplasmosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the histoplasmosis treatment industry. This histoplasmosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The histoplasmosis treatment consists of sales of antifungal medications and posaconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.